Future of Medicare drug price negotiations under new administration: 5 things to know

(By Alexandra Murphy for Becker’s Hospital Review)

As President-elect Donald Trump prepares to take office, the future of Medicare’s drug price negotiation program, part of the 2022 Inflation Reduction Act, is uncertain, Roll Call reported Nov. 15.

The program, which allows the federal government to negotiate prices for high-cost drugs, is a key policy achievement of the Biden administration, but its future could be affected by changes under the new administration and Congress. Continue reading here…

Notice: The link provided above connects readers to the full content of the posted article. The URL (internet address) for this link is valid on the posted date; medicarereport.org cannot guarantee the duration of the link’s validity. Also, the opinions expressed in these postings are the viewpoints of the original source and are not explicitly endorsed by AMAC, Inc.; the AMAC Foundation, Inc.; or medicarereport.org.